Skip to main content

Artelo Biosciences, Inc.

corporate_fare Company Profile

Artelo Biosciences, Inc.

ARTL·NASDAQ·Life Sciences·CIK 0001621221

The company, incorporated in Nevada on May 2, 2011, and based in San Diego, California, is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing treatments that target lipid-signaling modulation pathways, including the endocannabinoid system. The company's product pipeline utilizes scientific methodologies to develop pharmaceuticals for patients with unmet healthcare needs. Its primary program involves ART27.13, a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule, a G protein-coupled receptor (GPCR), was initially developed by AstraZeneca plc. The company is developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial called the Cancer Appetite Recovery Study (CAReS). An interim analysis of the ongoing Phase 2a CAReS trial showed that patients with cancer anorexia receiving ART27.13 had a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to Phase 1b, even at doses up to twice the previous maximum. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome. The company's second program, ART26.12, is a small molecule and the lead product candidate from its chemical library of inhibitors of fatty acid binding proteins, specifically Fatty Acid Binding Protein 5 (FABP5). The company received U.S. Food & Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for ART26.12 in July 2024 and has completed enrollment for a Phase 1 clinical trial in healthy subjects. This trial supports the development of ART26.12 as an agent intended to treat chemotherapy-induced peripheral neuropathy (CIPN).

Artelo Biosciences, Inc. (NASDAQ:ARTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for ARTL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Artelo Biosciences Files S-1 for Highly Dilutive $12.96M Offering to Address Going Concern and Nasdaq Compliance
  • Artelo Biosciences Secures $310K in Highly Dilutive Bridge Financing Amidst Going Concern
  • Fully Funded Glaucoma Study for Artelo's ART27.13 Expands Pipeline, Mitigates Cash Burn
  • Artelo Biosciences Confirms Reverse Split, Discloses Going Concern, and Secures $25M Equity Line
  • Artelo Biosciences Files to Effect 1-for-3 Reverse Stock Split to Boost Share Price

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$12.88M
Diluted EPS
-$12.52
Op. Cash Flow
-$8.52M
Operating Income
-$11.4M
Cash & Equivalents
$600K
Debt / Equity
0.00×
Shares Outstanding
2.02M sh
Source: 10-K · filed 2026-02-24 · accession 0001640334-26-000368
$1.39
52-week range · as of 2026-11-12 $1.39 – $179.19
Market cap
$1.3M
Volume
52K (1.4× avg)
3-mo avg 37.2K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARTL - Filings & News (Page 3)

ARTL
Mar 20, 2026, 5:18 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $7.63
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Mar 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.75
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Mar 18, 2026, 7:41 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.41
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Mar 17, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.06
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Mar 06, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.01
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Mar 06, 2026, 8:03 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Feb 24, 2026, 8:01 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.45
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Feb 05, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Feb 05, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.43
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jan 30, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.71
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jan 16, 2026, 5:16 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.59
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jan 02, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets